All In Biotech

NDA 202811 · Abbvie

Linzess

Linaclotide · Oral · Guanylate Cyclase-C Agonist

Novel

Last checked: Nov 19, 2026Latest source record: May 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Aug 30, 2012

Approved uses

6

Original approval plus efficacy supplements

Registered trials

53

16 Phase 3, 1 recruiting

FAERS reports

27,305

9,962 serious, 1,100 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE LINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.4 )]. WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE See full prescribing information for complete boxed warning. LINZESS is contraindicated in patients less than 2 years of age; in neonatal mice, linaclotide caused deaths due to dehydration. ( 4 , 5.1 , 8.4 )

What it is approved for

From the label in effect Oct 10, 2026.

LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 2 years of age and older LINZESS is a guanylate cyclase-C agonist indicated for treatment of: Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older. ( 1 ) Chronic idiopathic constipation (CIC) in adults. ( 1 ) Functional constipation (FC) in pediatric patients 2 years of age and older. ( 1 )

Mechanism: Linaclotide is structurally related to human guanylin and uroguanylin and functions as a guanylate cyclase-C (GC-C) agonist. Both linaclotide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • LINZESS · LINACLOTIDE 72MCG · CAPSULE, ORAL · Prescription · TE AB
  • LINZESS · LINACLOTIDE 145MCG · CAPSULE, ORAL · Prescription · TE AB
  • LINZESS · LINACLOTIDE 290MCG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Linaclotide" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea4,777
  • drug ineffective4,586
  • off label use3,406
  • constipation2,071
  • nausea1,522
  • fatigue1,213
  • abdominal distension1,188
  • abdominal pain1,089
  • headache1,073
  • pain991
  • abdominal pain upper969
  • dizziness879

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20129
2013597
20141,295
20151,290
20162,129
20172,256
20182,579
20192,374
20202,225
20211,937
20221,882
20231,994
20242,049
20252,478
20262,211

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Linzess (Linaclotide)

2024 spending

$1.98B

Beneficiaries

632,063

2,506,531 claims

Per beneficiary

$3,136

$17.69 per unit

View as table
YearSpending
2020$1,144,468,128
2021$1,374,354,961
2022$1,581,669,987
2023$1,825,245,843
2024$1,981,958,629

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 88 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.